Table 1.
Main data about MTC and DTC patients treated with LRTs for LMs
| pt | Histology (age*) |
LM | Other sites of metastases |
Concomitant TKI treatment |
LRT | No. of treated LM |
Size of largest treated LM | Response of treated LM |
|---|---|---|---|---|---|---|---|---|
| 1 |
MTC (41 years) |
Multiple | - | No | TACE | 3 | 18 mm | PR |
| 2 |
MTC (23 years) |
Multiple | - | No | TACE | 2 | 42 mm | PD |
| Yes (vandetanib) | RFA | 2 | 18 mm | PR | ||||
| 3 |
DTC (55 years) |
Single | Bone, lung | No | MWA | 1 | 55 mm | SD |
| No | MWA + TACE | 1 | 50 mm | SD | ||||
| 4 |
DTC (71 years) |
Multiple | Bone, brain, lung |
Yes (lenvatinib) |
TACE | 4 | 32 mm | SD |
DTC differentiated thyroid cancer, LRT loco-regional treatment, LM liver metastasis, MTC medullary thyroid cancer, MWA microwave ablation, PD disease progression, PR partial response, RFA radiofrequency ablation, SD stable disease, TACE trans-arterial chemoembolization, TKI tyrosine kinase inhibitor
*Age at diagnosis of LM